Standout Papers
- Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021)
- Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW. (2024)
Citation Impact
2 by Nobel laureates 5 from Science/Nature 58 standout
Citing Papers
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Natural killer cell therapies
2024 StandoutNature
Works of David Tai being referenced
Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
2021 Standout
Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study
2021
Author Peers
| Author | Oncology | Hepatology | PRM | Molecular Biology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| David Tai | 700 | 494 | 291 | 348 | 75 | 1.7k | |
| G. Lamarche | 26 | 70 | 1.2k | ||||
| Martine Kemmer | 230 | 10 | 13 | 473 | |||
| Nakao Akutsu | 25 | 497 | |||||
| Shane Kelly | 11 | 23 | 1.0k | ||||
| Kees Kok | 9 | 282 |
All Works
Login with ORCID to disown or claim papers
Loading papers...